The phosphoinositide 3-kinase/Akt1/Par-4 axis: A cancer-selective therapeutic target

Anindya Goswami, Padhma Ranganathan, Vivek M. Rangnekar

Research output: Contribution to journalReview articlepeer-review

88 Scopus citations


Activation of the phosphoinositide 3-kinase (PI3K)/Akt cell survival pathway in many cancers makes it an appealing target for therapeutic development. However, because this pathway also has an important role in the survival of normal cells, tactics to achieve cancer selectivity may prove important. We recently showed that the cancer-selective proapoptotic protein Par-4 is a key target for inactivation by PI3K/Akt signaling. Additionally, we found that Par-4 participates in mediating apoptosis by PTEN, the tumor suppressor responsible for blocking PI3K/Akt signaling. As a central player in cancer cell survival, Par-4 may provide a useful focus for the development of cancer-selective therapeutics.

Original languageEnglish
Pages (from-to)2889-2892
Number of pages4
JournalCancer Research
Issue number6
StatePublished - Mar 15 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The phosphoinositide 3-kinase/Akt1/Par-4 axis: A cancer-selective therapeutic target'. Together they form a unique fingerprint.

Cite this